Fisetin with PRP and losartan for hip impingement: pilot RCT results not reported
This was a pilot RCT investigating whether the senolytic agent fisetin, combined with platelet-rich plasma (PRP) and losartan, could improve outcomes in patients undergoing hip arthroscopy for femoroacetabular impingement and labral tear. The study aimed to assess clinical outcomes, safety, and markers of senescence and fibrosis, but the abstract reports study objectives and design only—no results are presented.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 16, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients suffering from femoroacetabular impingement and labral tear who are planning to undergo hip arthroscopy, recruited from The Steadman Clinic
- Primary outcome
- Improvement in beneficial effects of PRP when used with surgical treatment of femoroacetabular impingement and/or labral tear
- Effect size
- —
- Significance
- Not reported
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Sources
Primary source
- Steadman Philippon Research Institute ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.